MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.msard.2024.105732

Медицинская библиотека · Multiple sclerosis and related disorders · 2024

Preferences for neuromyelitis optica spectrum disorder treatments: A conjoint analysis with neurologists in Spain.

Téllez-Lara Nieves, Gómez-Ballesteros Rocío, Sepúlveda María, Orviz Aida, Díaz-Sánchez María, Boyero Sabas, Aguado-Valcarcel Marta, Cobo-Calvo Álvaro, López-Laiz Paloma, Rebollo Pablo, Maurino Jorge

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The treatment landscape for neuromyelitis optica spectrum disorder (NMOSD) has changed in recent years with the approval of therapies with different efficacy, safety and administration profiles.

OBJECTIVE

The aim of this study was to assess neurologists' preferences for different NMOSD treatment attributes using conjoint analysis (CA).

METHODS

We conducted an online, non-interventional, cross-sectional study in collaboration with the Spanish Society of Neurology. Our CA assessed five drugs' attributes: prevention of relapse, prevention of disability accumulation, safety risk, management during pregnancy, and route and frequency of administration. Participants were presented with eight hypothetical treatment scenarios to rank based on their preferences from the most preferred to the least. An ordinary least squares method was selected to estimate weighted preferences.

RESULTS

A total of 104 neurologists were included. Mean age (standard deviation-SD) was 37.7 (10.3) years, 52.9 % were male, and median time (interquartile range) of experience managing NMOSD was 5.0 (2.9, 10.8) years. Neurologists placed the greatest importance on efficacy attributes, time to relapse (44.1 %) being the most important, followed by preventing disability accumulation (36.8 %). In contrast, route and frequency of administration (4.6 %) was the least important characteristic. Participants who prioritised efficacy attributes felt more comfortable in decision-making, had fewer past experiences of care-related regret and a lower attitude to risk taking than their counterparts.

CONCLUSION

Neurologists' treatment preferences in NMOSD were mainly driven by efficacy attributes. These results may be useful to design policy decisions and treatment guidelines for this condition.

Для цитирования: Téllez-Lara Nieves, Gómez-Ballesteros Rocío, Sepúlveda María, Orviz Aida, Díaz-Sánchez María, Boyero Sabas, Aguado-Valcarcel Marta, Cobo-Calvo Álvaro, López-Laiz Paloma, Rebollo Pablo, Maurino Jorge. Preferences for neuromyelitis optica spectrum disorder treatments: A conjoint analysis with neurologists in Spain.. Multiple sclerosis and related disorders. 2024. DOI: 10.1016/j.msard.2024.105732.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.